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High-risk neuroblastoma remains one of the dead-
liest childhood cancers. Identification of metabolic
pathways that drive or maintain high-risk neuroblas-
tomamay open new avenues of therapeutic interven-
tions. Here, we report the isolation and propagation
of neuroblastoma sphere-forming cells with self-
renewal and differentiation potential from tumors of
the TH-MYCN mouse, an animal model of high-risk
neuroblastoma with MYCN amplification. Transcrip-
tional profiling reveals that mouse neuroblastoma
sphere-forming cells acquire a metabolic program
characterized by transcriptional activation of the
cholesterol and serine-glycine synthesis pathways,
primarily as a result of increased expression of sterol
regulatory element binding factors and Atf4, respec-
tively. This metabolic reprogramming is recapitu-
lated in high-risk human neuroblastomas and is
prognostic for poor clinical outcome. Genetic and
pharmacological inhibition of the metabolic program
markedly decreases the growth and tumorigenicity
of both mouse neuroblastoma sphere-forming cells
and human neuroblastoma cell lines. These findings
suggest a therapeutic strategy for targeting the
metabolic program of high-risk neuroblastoma.
INTRODUCTION
Neuroblastoma is a common pediatric cancer of the sympa-
thetic nervous system that arises in the adrenal medulla andCe
This is an open access article under the CC BY-Nparavertebral sympathetic ganglia (Brodeur, 2003; Cheung
and Dyer, 2013; Maris et al., 2007). Neuroblastoma is classi-
fied into low-, intermediate-, and high-risk categories (Cohn
et al., 2009). Patients with low- or intermediate-risk neuroblas-
toma have an overall survival rate of more than 90% following
minimum or standard treatment. However, the overall survival
rate for patients with high-risk neuroblastoma is less
than 50%, even after intensive, multimodal therapy in combi-
nation with bone marrow transplant (Park et al., 2013; Pinto
et al., 2015). A better understanding of the molecular basis
of high-risk neuroblastoma may suggest new therapeutic
strategies.
The most common genetic alterations associated with high-
risk neuroblastoma are MYCN amplification, 1p loss, 11q
deletion, or 17q gain (Cohn et al., 2009). Neuroblastomas with
amplification of the oncogene MYCN are generally classified as
high risk (Cohn et al., 2009) and are often associated with 1p
loss and 17q gain (Bown, 2001; Caron, 1995; Cheng et al.,
1995; Komuro et al., 1998). Approximately half of high-risk
neuroblastomas carry noMYCN amplification but frequently har-
bor 11q deletion with or without 17q gain (Attiyeh et al., 2005;
Care´n et al., 2010; Guo et al., 1999; Luttikhuis et al., 2001). In
general, high-risk neuroblastomas show an unfavorable histol-
ogy, comprising predominantly Schwannian stroma-poor, undif-
ferentiated or poorly differentiated tumors (Cohn et al., 2009;
Shimada et al., 1999).
TH-MYCN transgenic mice have been widely used as an ani-
mal model for high-risk neuroblastomas with MYCN amplifica-
tion (Dyer, 2004). These mice express humanMYCN in migrating
neural crest cells under control of the rat tyrosine hydroxylase
(TH) gene promoter (Weiss et al., 1997) and develop tumors
that, in most cases, are histologically undifferentiated or poorly
differentiated (Moore et al., 2008). Gene expression profilingll Reports 17, 609–623, October 4, 2016 ª 2016 The Author(s). 609
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
has revealed that TH-MYCN tumors are molecularly similar to
International Neuroblastoma Staging System (INSS) stage 3–4
human neuroblastomas with MYCN amplification (Teitz et al.,
2011). Neuroblastoma development in TH-MYCN mice begins
with multifocal hyperplasia in early postnatal sympathetic
ganglia characterized as clusters of small round blue cells on
H&E-stained sections. These hyperplastic lesions either regress
spontaneously or develop into neuroblastomas (Hansford et al.,
2004). Examination of stage- and lineage-specific markers has
revealed that the hyperplasia is composed predominantly of
highly proliferative Phox2B+ neuronal progenitors with undetect-
able expression of differentiation markers, whereas neuroblas-
toma tumors contain several distinct cell subpopulations,
including Phox2B+TH, Phox2B+TH+, and Phox2BTH+ cells
(Alam et al., 2009). Phox2B (paired like homeobox 2b) is a tran-
scription factor that is expressed in sympathetic progenitors
and is essential for embryonic development of the sympathetic
nervous system (Pattyn et al., 1999), and TH is the first and
rate-limiting enzyme in catecholamine biosynthesis that is highly
expressed in differentiated sympathetic neurons (Goridis and
Rohrer, 2002). Thus, TH-MYCN tumors are heterogeneous at
the cellular level, consisting of tumor cells with varying degrees
of differentiation.
It has been reported that histologically poorly differentiated
tumors, regardless of their tissue origins, display a molecular
similarity to embryonic stem cells (ESCs), as evidenced by the
coordinated up- or downregulation of gene sets associated
with ESC identity (Ben-Porath et al., 2008). This led us to hy-
pothesize that gene expression profiling of undifferentiated TH-
MYCN tumor cells with stem cell properties might help uncover
the molecular mechanisms underlying high-risk neuroblastoma.
Our investigation revealed that TH-MYCN neuroblastoma
sphere-forming cells and high-risk human neuroblastomas share
a common metabolic program for growth and tumorigenicity.
RESULTS
TH-MYCN Neuroblastoma Sphere-Forming Cells
Possess Self-Renewal Capacity
Sphere-forming assays have been widely used to isolate, prop-
agate, and characterize normal and cancer stem cells (Pastrana
et al., 2011). In this assay, stem cells grow as spheres in serum-
free medium containing basic fibroblast growth factor and
epidermal growth factor, with or without various tissue extracts
and supplements (Reynolds and Weiss, 1992; Singh et al.,
2003). In spite of extensive efforts, we were unable to obtain
long-term (>2 months) sphere culture from primary TH-MYCN
tumors (n > 20) using various serum-free culture systems or
ATCC mouse embryonic stem cell medium containing 10%–
20% fetal bovine serum (FBS). We next tried a culture medium
for primary neural crest cells that contains 12% FBS plus other
supplements (Etchevers, 2011), based on the reasoning that
neuroblastoma arises in tissues originating from the neural crest
(Le Douarin and Dupin, 1993) and that sympathetic neural crest
cells or progenitors are likely to be the cell of origin for neuroblas-
toma (Cheung and Dyer, 2013; Marshall et al., 2014; Schulte
et al., 2013). With this culture system, we were able to grow
and propagate spheres from all 28 primary TH-MYCN tumors610 Cell Reports 17, 609–623, October 4, 2016examined so far (Figure 1A). In all cases, only a small population
of primary tumor cells (presumably those with neural crest cell
properties) was able to survive and proliferate in culture. In gen-
eral, primary spheres appeared after 2 weeks of culture and then
underwent rapid proliferation (Figure 1B). The sphere culture
could be passaged continuously for at least 6 months. Immuno-
fluorescence staining showed that a majority of sphere cells
displayed nuclear expression of MYCN and Phox2B (Figures
S1A and S1B, left), which are specific markers for progenitor
cells or neuroblasts in TH-MYCN neuroblastoma tumors (Alam
et al., 2009). In addition, we observed high levels of TH expres-
sion in a small population of sphere cells (Figures S1A and
S1B, left). Together, these data provide evidence for neuroblas-
toma origin of these sphere cells.
To determine whether the sphere cells possess self-renewal
potential, we performed serial sphere-forming assays with single
sphere cells. In principle, a sphere is dissociated into single cells
and replated at clonal density or a single cell per well. Formation
of new spheres that maintain the ability to differentiate demon-
strates self-renewal (Pastrana et al., 2011; Reynolds and Weiss,
1992; Singec et al., 2006). Primary spheres (Figure 1A, ‘‘1st
sphere’’) were mechanically dissociated into single cells, which
were then plated at the frequency of 1 cell per well in 96-well
plates. Those wells with a single cell were confirmed by micro-
scopy and marked. The resultant secondary spheres (Figure 1C,
‘‘2nd sphere’’) were again dissociated into single cells and
replated at 1 cell per well for the generation of tertiary spheres
(Figure 1D, ‘‘3rd sphere’’). Similar to primary spheres, single-
cell-derived secondary and tertiary spheres were composed
predominantly of MYCN- and Phox2B-positive cells with or
without TH expression (Figures S1A and S1B, middle and right).
These findings demonstrate, at the single-cell level, that a sub-
population of mouse neuroblastoma sphere cells possesses
self-renewal and differentiation potential as evidenced by their
capacity to generate new spheres composed of distinct subpop-
ulations of progeny cells found in primary spheres. With these
assays, we estimated that the frequency of sphere-forming cells
within primary mouse tumors was 0.18% (n = 5), which was
increased to 22.3% and 23.2% for primary and secondary
spheres, respectively (Figure 1E).
We next performed serial tumorigenic transplantation assays
to demonstrate the ability of mouse neuroblastoma spheres to
self-renew in vivo (Clarke et al., 2006; Lathia et al., 2015).
Compared to their parental tumor cells, clonal primary sphere
cells showed a marked increase (>100-fold) in the capacity to
generate new tumors in syngeneic wild-type 129X1/SvJ mice
and in immunodeficient NOD.SCID/NCr mice (Figures 1F and
1G). The secondary tumors derived from the sphere cells dis-
played histopathological features and molecular marker expres-
sion identical to their parental primary tumors (Figures 1H, S1C,
and S1D, primary versus 2nd tumor). Likewise, spheres derived
from the secondary tumors were able to generate tertiary tumors
that phenocopied the primary and secondary tumors (Figures
1H, S1C, and S1D, third tumor). Collectively, these data demon-
strate that mouse neuroblastoma spheres contain a subpopula-
tion of sphere-forming cells that are able to self-renew and
generate new tumors with the phenotypic heterogeneity found
in the parental tumors.
Figure 1. TH-MYCN Neuroblastoma Sphere-Forming Cells Possess Self-Renewal and Tumorigenic Potential
(A) Phase-contrast images of MYCN-787 primary tumor cells at the day of plating (0 day, left) and primary (1st) spheres after 23 days of culture (right).
(B) Growth assays of MYCN-750 and MYCN-787 primary tumor cells. Spheres appeared after 2 weeks of culture. Viable cells were quantified by trypan blue
staining. Error bars represent SD (n = 4).
(C and D) Phase-contrast images of serial sphere-forming assays of single cell-derived MYCN-787 secondary (C, 2nd) and tertiary (D, 3rd) spheres.
(E) Quantification of sphere-forming cell frequency in primary tumors, 1st and 2nd spheres.
(F and G) Tumor transplantation assays for primary tumor cells and primary sphere cells in syngeneic 129X1/SvJ (F) and NOD.SCID/NCr (G) mice.
(H) Serial tumor transplantation assays with H&E (top) and immunofluorescence (bottom) staining of an MYCN-787 primary tumor, a representative 2nd tumor
generated by MYCN-787 primary spheres, and a representative 3rd tumor by spheres from the 2nd tumor. Nuclei were stained with DAPI.
See also Figure S1.TH-MYCN Neuroblastoma Sphere-Forming Cells
Undergo Spontaneous and Retinoic-Acid-Induced
Differentiation
Single sphere cells were able to generate new spheres
composed of distinct subpopulations of cells expressingdifferent levels of the progenitor marker Phox2B with or without
expression of the differentiation marker TH (Figure S1B).
This observation indicates that TH-MYCN neuroblastoma
sphere-forming cells underwent spontaneous differentiation in
culture. We further investigated the responsiveness of theseCell Reports 17, 609–623, October 4, 2016 611
Figure 2. Retinoic Acid Induces Growth Arrest and Differentiation of Neuroblastoma Sphere-Forming Cells
(A and B) Phase-contrast images (A) and quantification (B) of spheres treated with DMSO or 10 mM RA. Error bars (B) represent SD (n = 3).
(C) Growth assays of spheres treated with DMSO or 10 mM RA. Viable cells were quantified by trypan blue staining. Error bars represent SD (n = 4). Data were
analyzed by two-way ANOVA with p values indicated.
(D and E) Tumor transplantation assay of spheres treated with DMSO or 10 mMRA for 7 days. Tumor weight (E) was analyzed by scatterplot, with horizontal lines
indicating the mean.
(F) qRT-PCR analysis of mRNA expression in spheres treated with DMSO or 10 mM RA. Error bars represent SD (n = 3).
Unless indicated, data were analyzed with a two-tailed Student’s t test. ***p < 0.001. See also Figure S2.sphere-forming cells to retinoic acid (RA), a differentiation
inducer of neuroblastoma cells (Sidell, 1982) and neural crest
cells (Dupin and LeDouarin, 1995; Huang et al., 2016). Treatment
of mouse neuroblastoma spheres with RA induced growth arrest
as evidenced by the marked reduction in sphere size and
numbers, as well as the total number of sphere cells (Figures
2A–2C). Consistent with the growth arrest phenotype in culture,
RA treatment markedly inhibited the tumorigenicity of sphere
cells (Figures 2D and 2E).
Most of the spheres that were treated with RA for an extended
period of time became attached to the culture dish and displayed
morphologic features of neuronal differentiation, such as
extensive neurite outgrowth (Figure S2). qRT-PCR revealed
significant upregulation of neuronal differentiation genes,
including Gfra3 and Ntn3 (Figure 2F), which are known to be
upregulated in neuroblastoma cells undergoing neuronal differ-
entiation (Mao et al., 2011; Wang et al., 2013, 2014). As ex-
pected, we also observed a significant decrease in Phox2B
expression in spheres treated with RA (Figure 2F). It is known
that Phox2B expression is downregulated during sympathetic
neuron differentiation (Alam et al., 2009) and RA-induced neuro-
blastoma differentiation (Mao et al., 2011). Together, these find-
ings demonstrate that mouse neuroblastoma sphere-forming
cells possess the differentiation capacity of their cell of origin.612 Cell Reports 17, 609–623, October 4, 2016Cholesterol and Serine-Glycine Synthesis Pathways
Are Transcriptionally Activated in Neuroblastoma
Sphere-Forming Cells
To gain a molecular understanding of TH-MYCN neuroblastoma
sphere-forming cells, we performedmicroarray gene expression
profiling of three independent lines of sphere-forming cells in
comparison with their parental primary tumors. A total of 2,376
genes showed significant changes in expression (R ±1.5-fold,
p < 0.05), with 1,261 genes being downregulated and 1,115
genes upregulated in neuroblastoma spheres (Table S1). The
downregulated genes are highly enriched for Gene Ontology
(GO) terms associated with neuronal differentiation, including
axonogenesis and neuron morphogenesis (Figure S3A; Table
S2). We obtained similar results with PANTHER (protein analysis
through evolutionary relationships) analysis of the downregu-
lated genes, which are highly enriched for PANTHER terms asso-
ciatedwith neurogenesis and synaptic transmission (Figure S3B;
Table S2). These findings provide further evidence, at the molec-
ular level, that neuroblastoma sphere-forming cells are less
differentiated than their parental primary tumor cells.
For genes upregulated in neuroblastoma sphere-forming cells,
GO analysis revealed significant enrichment for GO terms asso-
ciated with the biosynthesis of the serine family of amino acids
and cholesterol (Figure 3A; Table S2). Expression levels of all
genes within the two biosynthetic pathways were increased in
neuroblastoma sphere-forming cells (Figures 3B and 3C). Gene
set enrichment analysis (GSEA) of the microarray data also
showed significantly higher expression of genes coding for
enzymes involved in cholesterol biosynthesis (Figure 3D). We
confirmed the microarray data by qRT-PCR, which showed sig-
nificant downregulation of the neuronal genes Gfra3 and Ntn3
and upregulation of serine-glycine and cholesterol pathway
genes, including Hmgcs1, Hmgcr, Mvk, Phgdh, Psat1, Psph,
and Shmt2 (Figure 3E). Immunofluorescence staining of tumors
generated by sphere-forming cells further confirmed the upregu-
lation of serine-glycine pathway genes Phgdh and Psat1 in less
differentiated TH neuroblastoma cells in comparison with
differentiated TH+ cells (Figure S3C).
In addition, our microarray data revealed transcriptional
upregulation of genes involved in neural crest cell migration and
anti-apoptosis, including Ret and Bcl2 (Tables S1 and S2), which
are known to be important in the pathogenesis of neuroblastoma
(Cazes et al., 2014; Ham et al., 2016). The data provide further ev-
idence for neural crest originofTH-MYCNneuroblastomasphere-
forming cells and their relevance to neuroblastoma development.
We have shown previously that differentiation of human neuro-
blastoma cells is associated with transcriptional downregulation
ofmetabolic pathways for cholesterol and serine-glycine synthe-
sis (Wang et al., 2014) (see also Figure S3D). In agreement with
the previous observation, qRT-PCR analysis of neuroblastoma
sphere-forming cells treated with RA showed a marked reduc-
tion in mRNA expression of Hmgcs1, Hmgcr, Mvk, Phgdh,
Psat1, Psph, and Shmt2 (Figure 3F).
Collectively, these data reveal a metabolic program in neuro-
blastoma sphere-forming cells that is characterized by increased
transcriptional activation of serine-glycine and cholesterol
synthesis pathway genes when compared with their parental
primary tumors. This metabolic program is associated with the
undifferentiated state of neuroblastoma sphere-forming cells.
Cholesterol and Serine-Glycine Synthesis Pathways
Are Essential for Maintaining Neuroblastoma
Sphere-Forming Cells
We next examined the biological significance of the metabolic
program in neuroblastoma sphere-forming cells by blocking
the serine-glycine and cholesterol synthesis pathways. We
treated neuroblastoma sphere-forming cells with statins, a class
of cholesterol-lowering drugs that inhibit Hmgcr, the rate-limiting
enzyme in cholesterol synthesis (Figure 3C). Both simvastatin
and fluvastatin markedly inhibited the ability of neuroblastoma
sphere-forming cells to grow in culture (Figures 4A and S4A).
The addition of mevalonate, the metabolite immediately down-
stream of Hmgcr (Figure 3C), fully rescued the anti-growth effect
of simvastatin (Figure 4B), demonstrating that the statins target
Hmgcr to inhibit the growth of neuroblastoma sphere-forming
cells. Moreover, simvastatin treatment for 24 hr completely abol-
ished the ability of neuroblastoma sphere-forming cells to
generate tumors in immunodeficient mice (Figure 4C). Thus,
the cholesterol synthesis pathway is essential for the growth
and tumorigenicity of neuroblastoma sphere-forming cells.
We also found an essential role of the serine-glycine synthesis
pathway in maintaining neuroblastoma sphere-forming cells.Small hairpin RNA (shRNA)-mediated knockdown of Phgdh
expression (Figures 4D and S4B), the first enzyme in the pathway
(Figure 3B), exerted a pronounced inhibitory effect on the growth
(Figures 4E and S4C) and tumorigenicity (Figure 4F) of sphere-
forming cells.
Srebf and Atf4 Activate the Metabolic Program in
Neuroblastoma Sphere-Forming Cells
To gain a molecular understanding of the metabolic reprogram-
ming in mouse neuroblastoma sphere-forming cells, we
examined the microarray data by GSEA for identifying potential
upstream transcription factors. The analysis revealed significant
upregulation of the gene set consisting of direct targets of sterol
regulatory element binding transcription factors (Srebf) in
sphere-forming cells relative to their parental primary tumor cells
(Figure 5A). Consistent with this finding, both microarray and
qRT-PCR analyses showed increased expression of Srebf1
and Srebf2 in sphere-forming cells (Table S1; Figure 5B). It is
well established that Srebf2 has a major role in transcriptional
activation of the cholesterol pathway (Brown and Goldstein,
1997; Horton et al., 2002, 2003). To determine whether the
increased Srebf expression is responsible for transcriptional
activation of the cholesterol pathway in sphere-forming cells,
we treated these cells with fatostatin, a small-molecule inhibitor
of Srebf activation (Kamisuki et al., 2009). Fatostatin treatment
completely ablated the upregulation of key cholesterol pathway
genes in sphere-forming cells (Figures 5C and S5A) and mark-
edly inhibited their growth in culture (Figures 5D and S5B). We
obtained essentially the same results with betulin (Figures S5C
and S5D), which is also a small-molecule inhibitor of Srebf acti-
vation (Tang et al., 2011). These data indicate that increased
Srebf expression is essential for transcriptional activation of
the cholesterol pathway in neuroblastoma sphere-forming cells.
GSEA also revealed significant upregulation of activating tran-
scription factor 4 (Atf4) and its target genes in neuroblastoma
sphere-forming cells (Figures 5E and S5E). Atf4 can directly acti-
vate the transcription of serine-glycine pathway genes (Adams,
2007; Ding et al., 2013; Seo et al., 2009; Ye et al., 2012; Zhao
et al., 2016). We confirmed the upregulation of Atf4 in sphere-
forming cells by qRT-PCR (Figure 5F). Knockdown of Atf4
expression significantly decreased the expression of Phgdh
and Psat1 (Figure 5G) and markedly inhibited the survival and
proliferation of sphere-forming cells (Figures 5H and S5F). These
findings suggest that increased Atf4 expression has a major role
in transcriptional activation of the serine-glycine pathway in
neuroblastoma sphere-forming cells.
The Metabolic Program of Neuroblastoma Sphere-
Forming Cells Is Essential for the Growth and
Tumorigenicity of Human Neuroblastoma Cells
To test the relevance of above findings to human neuroblastoma,
we first examined the functional significance of the metabolic
program of mouse neuroblastoma sphere-forming cells in human
neuroblastoma cell lines. Pharmacological inhibition of the choles-
terol pathway by simvastatin induced growth arrest or cell death in
all humanneuroblastomacell linesexamined (Figures6AandS6A).
Again, this inhibitory effect could be fully rescued by supplemental
mevalonate (Figures 6B, S6B, and S6C), demonstrating thatCell Reports 17, 609–623, October 4, 2016 613
Figure 3. Transcriptional Activation of the Cholesterol and Serine-Glycine Pathways in Neuroblastoma Sphere-Forming Cells
(A) GO analysis of genes upregulated in neuroblastoma sphere-forming cells in comparison with their parental primary tumor cells. Shown are the top ten GO
biological process terms based on fold enrichment.
(B and C) Fold changes in mRNA expression of genes in the serine-glycine (B) and cholesterol (C) pathways determined by microarray analysis.
(legend continued on next page)
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Figure 4. Cholesterol and Serine-Glycine Pathways Are Essential for Maintaining Neuroblastoma Sphere-Forming Cells
(A) Growth assays of neuroblastoma sphere-forming cells treated with DMSO, increasing concentrations of simvastatin (Simva) or 2 mM fluvastatin (Fluva). Error
bars represent SD (n = 4). Data were analyzed by two-way ANOVA with p values indicated.
(B) Growth assays of neuroblastoma sphere-forming cells treated with DMSO and Simvawith or without mevalonate (Meval). Error bars represent SD (n = 4). Data
were analyzed by two-way ANOVA, and p values are indicated.
(C) Tumor transplantation assay of neuroblastoma sphere-forming cells treated with DMSO or 5 mM Simva for 24 hr. Tumor weight was analyzed by scatterplot,
with horizontal lines indicating the mean.
(D) qRT-PCR analysis of Phgdh mRNA levels in neuroblastoma sphere-forming cells infected with lentiviruses expressing shRNA against GFP or Phgdh. Error
bars represent SD (n = 3).
(E) Growth assays of neuroblastoma sphere-forming cells without or with Phgdh knockdown. Error bars represent SD (n = 4). Data were analyzed by two-way
ANOVA, and p values are indicated.
(F) Tumor transplantation assay of neuroblastoma sphere-forming cells without or with Phgdh knockdown. Tumor weight was analyzed by scatterplot, with
horizontal lines indicating the mean.
**p < 0.01; ***p < 0.001. See also Figure S4.simvastatin targets the cholesterol pathway in human neuroblas-
toma cells. Treatment of SK-N-AS and SMS-KCNR cells with
simvastatin for 24 hr significantly attenuated their tumorigenicity
in immunodeficient mice (Figure 6C). Of note, bothMYCN-ampli-
fied (IMR32,SK-N-BE(2), andSMS-KCNR)andnon-MYCN-ampli-
fied (CHLA-90, SHEP1, and SK-N-AS) neuroblastoma cell lines
were sensitive to simvastatin (Figures 6A and 6B).
We also examined the effect of blocking the serine-glycine
pathway. Knockdown of PHGDH expression by two indepen-
dent shRNA constructs (Figures 6D and 6E) essentially arrested
the growth of BE(2)-C and SK-N-AS cells in culture (Figure 6F).(D) GSEA showing significant enrichment of the gene set involved in choleste
sphere-forming cells.
(E and F) qRT-PCR analysis of mRNA expression of the indicated genes in neurob
(E) or treated with DMSO or 10 mM RA (F). Error bars represent SD (n = 3).
**p < 0.01; ***p < 0.001. See also Figure S3 and Tables S1 and S2.Collectively, these findings demonstrate that the metabolic
program of mouse neuroblastoma sphere-forming cells is
required for the growth and tumorigenicity of human neuroblas-
toma cell lines independent of their MYCN amplification status.
The Metabolic Program of Neuroblastoma
Sphere-Forming Cells Is Associated with High-Risk
Neuroblastoma and Is a Predictor of Poor Clinical
Outcome
To further assess the clinical relevance of our findings with
mouse neuroblastoma sphere-forming cells, we examined therol synthesis, with most of the genes being upregulated in neuroblastoma
lastoma sphere-forming cells in comparison with their parental primary tumors
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Figure 5. Srebf and Atf4 Mediate the Metabolic Reprogramming in Neuroblastoma Sphere-Forming Cells
(A) GSEA showing significant enrichment of Srebf targets. Most genes are upregulated in neuroblastoma sphere-forming cells relative to parental primary tumor
cells.
(B) qRT-PCR analysis of mRNA levels of Gfra3, Srebf1, and Srebf2 in neuroblastoma sphere-forming cells in comparison with their parental primary tumor cells.
Error bars represent SD (n = 3).
(C) qRT-PCR analysis of mRNA levels of cholesterol pathway genes in parental primary tumor cells and neuroblastoma sphere-forming cells treated with DMSO
or 10 mM fatostatin (Fato) for 48 hr. Error bars represent SD (n = 3).
(D) Growth assays of neuroblastoma sphere-forming cells treated with DMSO or fatostatin. Error bars represent SD (n = 4). Data were analyzed by two-way
ANOVA, and p values are indicated.
(E) GSEA showing significant enrichment of Atf4 targets. Most genes are upregulated in neuroblastoma sphere-forming cells relative to parental primary tumor
cells.
(F) qRT-PCR analysis of mRNA levels of Gfra3 and Atf4 in neuroblastoma sphere-forming cells relative to their parental primary tumor cells. Error bars represent
SD (n = 3).
(G) Immunoblot analysis of Atf4, Phgdh, and Psat1 levels relative to b-actin in neuroblastoma sphere-forming cells without or with Atf4 knockdown.
(H) Growth assays of neuroblastoma sphere-forming cells without or with Atf4 knockdown. Error bars represent SD (n = 4). Data were analyzed by two-way
ANOVA, and p values are indicated.
**p < 0.01; ***p < 0.001. See also Figure S5 and Table S1.correlation between the metabolic gene expression and clinical
outcomes using gene expression data from two independent
cohorts of neuroblastoma patients (n = 1,147). We focused our
analysis on the following key genes in the cholesterol and
serine-glycine pathways: HMGCS1 (catalyzing HMG-CoA syn-616 Cell Reports 17, 609–623, October 4, 2016thesis), HMGCR (rate-limiting enzyme of the cholesterol
pathway), SQLE (catalyzing the first cholesterol-specific step in
the cholesterol pathway), PHGDH and PSAT1 (the first two en-
zymes in the serine-glycine pathway), and SHMT2 (linking
glycine synthesis to one-carbon metabolism and nucleotide
Figure 6. Cholesterol and Serine-Glycine Pathways Are Essential for the Growth and Tumorigenicity of Human Neuroblastoma Cell Lines
(A) Growth assays of human neuroblastoma cell lines treated with DMSO or Simva. Error bars represent SD (n = 4). Data were analyzed by two-way ANOVA, and
p values are indicated.
(B) Survival assays of human neuroblastoma cell lines treated with DMSO or 5 mM Simva in the absence or presence of mevalonate. Error bars represent SD
(n = 4).
(C) Tumor transplantation assays of human neuroblastoma cell lines treated with 5 mMSimva for 24 hr. Tumor weight was analyzed by scatterplot, with horizontal
lines indicating the mean.
(D and E) qRT-PCR (D) and immunoblot (E) analyses of PHGDH expression in human neuroblastoma cell lines infected with lentiviruses expressing shGFP or
shPHGDH. Error bars (D) represent SD (n = 3).
(F) Growth assay of human neuroblastoma cell lines without or with PHGDH knockdown. Error bars represent SD (n = 4). Data were analyzed by two-way ANOVA,
and p values are indicated.
**p < 0.01; ***p < 0.001. See also Figure S6.production). The RNA-sequencing dataset from a clinical cohort
of 498 neuroblastomas contains clinical data regarding to risk
classification (high or low risk), tumor stages (INSS), and patient
survival (Zhang et al., 2015). Analysis of the dataset revealed that
high-risk neuroblastomas expressed these metabolic genes at
significantly higher levels in comparison with low-risk neuroblas-
tomas (Figure 7A), indicating that the metabolic program of
mouse neuroblastoma sphere-forming cells is also activated in
high-risk neuroblastomas. In line with this finding, we observed
significantly higher expression of these metabolic genes inINSS stage 3–4 neuroblastomas (Figure 7B). Analysis of prog-
nostic values of these metabolic genes revealed that higher
expression was associated with a significant decrease in
event-free survival (Figure 7C), as well as in overall survival
(data not shown). We further validated differential expression
of these metabolic genes in another cohort of 649 neuroblas-
tomas (Kocak et al., 2013). Higher expression of these metabolic
genes was significantly associated with advanced stages of
neuroblastomas and lower event-free survival (Figures S7A
and S7B).Cell Reports 17, 609–623, October 4, 2016 617
Figure 7. TheMetabolic Program of Neuroblastoma Sphere-Forming Cells Is Activated in High-Risk Neuroblastomas and Is Associated with
Poor Clinical Outcome
(A and B) Box plots of individual metabolic gene expression in relation to neuroblastoma risk groups (A) and INSS stages (B) using the SEQC-NB498 dataset. Data
were analyzed with a two-tailed Student’s t test, and p values are indicated.
(C) Event-free Kaplan-Meier survival curves for the SEQC cohort of 498 neuroblastoma patients based on differential expression of themetabolic genes. Log-rank
test p values are shown.
See also Figure S7.
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Given that the sphere-forming cells were isolated from
tumors of TH-MYCN mice, a model of human high-risk neuro-
blastomas with MYCN amplification, we asked whether our
findings are relevant to non-MYCN-amplified high-risk neuro-
blastomas. We further analyzed the NB498 dataset by
excluding patients with MYCN-amplified neuroblastoma, which
revealed significantly higher expression of HMGCR, SQLE,
PSAT1, and SHMT2 in non-MYCN-amplified high-risk neuro-
blastomas in comparison with low-risk neuroblastomas (Fig-
ure S7C). In addition, higher expression of all six metabolic
genes was significantly associated with worse prognosis for
patients carrying non-MYCN-amplified neuroblastomas
(Figure S7D).
Collectively, our analyses of human neuroblastoma gene
expression data indicate that regardless of MYCN amplification
status, high-risk and advanced neuroblastomas share the
metabolic program of mouse neuroblastoma sphere-forming
cells, characterized by transcriptional activation of the choles-
terol and serine-glycine synthesis pathways. Our findings also
suggest that themetabolic gene signature is of prognostic signif-
icance and predicts poor outcome.
DISCUSSION
In this study, we report the functional and molecular character-
ization of TH-MYCN mouse neuroblastoma sphere-forming
cells that possess self-renewal, differentiation, and tumorigenic
potential. These cells acquire a metabolic program character-
ized by higher mRNA expression of genes coding for enzymes
in the cholesterol and serine-glycine synthesis pathways, pri-
marily as the result of increased expression of Srebf and Atf4.
We present evidence that increased activation of these meta-
bolic pathways is essential for maintaining neuroblastoma
sphere-forming cells. Importantly, this metabolic program is
also activated in high-risk human neuroblastoma and is required
for the growth and tumorigenicity of human neuroblastoma
cells. These findings suggest key metabolic pathways for high-
risk neuroblastoma pathogenesis and maintenance, with thera-
peutic implications.
Neuroblastoma Sphere-Forming Cells
Our study provides evidence that within primary neuroblastoma
tumors from TH-MYCN mice, there is a small population of cells
with the ability to grow as spheres in the culture medium for pri-
mary neural crest cells (Etchevers, 2011). As estimated by
sphere-forming assays at clonal density, an average of 0.18%
of primary tumor cells were sphere-forming cells. Single-cell-
based serial sphere-forming assays revealed that 22%–23%
of sphere cells were able to generate new spheres. In addition
to serial sphere-formation assays in vitro, we also performed
serial tumor transplantation assays using clonal sphere cells,
which demonstrated that neuroblastoma sphere-forming cells
were able to generate new tumors in syngeneic and immuno-
deficient mice, exhibiting a marked increase (>100-fold) in
tumorigenic potential in comparison with primary tumor cells.
Thus, both in vitro and in vivo assays demonstrate the self-
renewal capacity of mouse neuroblastoma sphere-forming
cells.For their differentiation potential, we show that the spheres
were composed predominantly of MYCN+ and Phox2B+ cells,
with a small number of sphere cells expressing high levels of
the differentiation marker TH, with or without co-expression of
MYCN and Phox2B. Given the single-cell origin of secondary
and tertiary spheres, the finding of distinct cell subpopulations
within the spheres indicates spontaneous differentiation of
sphere-forming cells. Their differentiation potential was further
demonstrated by their ability to undergo RA-induced neuronal
differentiation. Finally, secondary and tertiary tumors generated
by clonal sphere cells fully recapitulated the cellular heterogene-
ity found in the parental tumors, which is characterized by
the presence of distinct subpopulations of Phox2B+TH,
Phox2B+TH+, and Phox2BTH+ cells (Alam et al., 2009).
While our data indicate that only a small population of pri-
mary tumor cells can give rise to spheres in culture, we would
like to point out that there are alternative explanations for the
low frequency observed, such as adaptation to culture condi-
tions and damage to cells as a result of mechanic stress during
tumor tissue dissociation. Nevertheless, our estimation sug-
gests that the neural crest cell culture system allowed for a
more than 100-fold enrichment of sphere-forming cells over pri-
mary tumors (23% in spheres versus 0.18% in primary tu-
mors). This is consistent with data from tumorigenic assays,
showing that the spheres had an over 100-fold increase
in the number of tumorigenic cells relative to primary tumors.
Efforts are underway to refine the culture system for minimizing
spontaneous differentiation. We are also analyzing the gene
expression data for identifying surface markers that allow us
to prospectively purify neuroblastoma sphere-forming cells,
which may also lead to more accurate quantification of these
cells in primary tumors.
The Metabolic Program in Neuroblastoma
Sphere-Forming Cells
It is well established that cancer cells reprogram their meta-
bolism to meet the energetic and biosynthetic requirements of
growth and proliferation. A major challenge is to identify the
metabolic pathways that specifically support the survival and
proliferation of cancer cells. Our isolation and transcriptional
profiling of TH-MYCN neuroblastoma sphere-forming cells re-
veals a metabolic program activated in this population of tumor-
igenic cells, which is defined by increased expression of genes
encoding enzymes within the cholesterol and serine-glycine
synthesis pathways. Functional assays demonstrated that this
metabolic program is essential for the maintenance of mouse
neuroblastoma sphere-forming cells.
There are clearly advantages in transcriptional activation of
these metabolic pathways for cell proliferation. The cholesterol
pathway, also known as the mevalonate pathway, is crucial for
the structure and function of cellular membranes and many
membrane localized proteins (Goldstein and Brown, 1990; Sil-
vente-Poirot and Poirot, 2012). Cholesterol is a structural
component of the cell membrane. Other important metabolites
generated from this pathway include ubiquinones, dolichols,
and isoprenoids required for the prenylation and activation of
Ras, Rho, and Rab families of proteins, which are known to
promote cell proliferation (Berndt et al., 2011).Cell Reports 17, 609–623, October 4, 2016 619
The serine-glycine pathway generates equimolar amounts of
NADH, a-ketoglutarate (a-KG), serine, glycine, and 5,10-me-
thylenetetrahydrofolate (5,10-MTHF). These metabolites are
required for the production of proteins, nucleic acids, fatty acids,
andmembranes needed for cell proliferation (Amelio et al., 2014;
DeBerardinis, 2011; Kalhan and Hanson, 2012; Locasale, 2013).
Glycine donates carbon and nitrogen moieties for purine
nucleotide synthesis. 5,10-MTHF is a coenzyme of thymidylate
synthase, which is required for de novo thymidylate biosyn-
thesis, and is a major source of one-carbon units for purine pro-
duction. Increased activation of the serine-glycine pathway can
also stimulate anaplerosis by supplying a-KG, which replenishes
tricarboxylic acid (TCA) cycle intermediates for biosynthesis
(DeBerardinis et al., 2007). In addition, serine-driven one-carbon
metabolism is a major pathway of NADPH production in prolifer-
ating cells (Fan et al., 2014). NADPH is required for the synthesis
of nucleotides, amino acids, and lipids and has a pivotal role in
maintaining the cellular redox balance (Schulze and Harris,
2012).
Our findings further suggest a molecular mechanism for the
increased activation of the metabolic program in neuroblas-
toma sphere-forming cells. Transcriptional profiling and qRT-
PCR showed a significant increase in the expression of Srebf1,
Srebf2, and Atf4 in neuroblastoma sphere-forming cells relative
to their parental primary tumor cells. Srebf2 has a major role in
transcriptional activation of the cholesterol pathway (Brown
and Goldstein, 1997; Horton et al., 2002, 2003), and Atf4 is a
key transcriptional activator of serine-glycine pathway genes
(Adams, 2007; Ding et al., 2013; Seo et al., 2009; Ye et al.,
2012; Zhao et al., 2016). In line with this model, pharmacolog-
ical inhibition of Srebf activation and shRNA-mediated silencing
of Atf4 were able to abrogate the transcriptional activation of
the cholesterol and serine-glycine pathways in neuroblastoma
sphere-forming cells, leading to a marked reduction in their
growth and tumorigenicity. There is evidence suggesting that
SREBFs and ATF4 may also play a role in activation of the
metabolic program in human neuroblastoma. We have shown
previously that ATF4 is required for the proliferation of human
neuroblastoma cells (Ding et al., 2013; Zhao et al., 2016), and
high expression of ATF4 and SREBF2 is significantly associ-
ated with poor prognosis in neuroblastoma patients (data not
shown).
Targeting High-Risk Neuroblastoma Metabolism
for Therapy
A key finding of our study is that the metabolic program
identified in mouse neuroblastoma sphere-forming cells is
also activated in high-risk neuroblastomas, regardless of
MYCN amplification status. Our analysis of gene expression
profiles of 1,147 neuroblastoma patients revealed that high-
risk neuroblastomas have significantly higher expression of
cholesterol and serine-glycine synthesis pathway genes in
comparison with low-risk neuroblastomas. Higher expression
of these metabolic genes is also significantly associated with
advanced stages of neuroblastomas and is a predictor of
poor clinical outcome. Moreover, this metabolic gene signature
could potentially serve as a biomarker for the differentiation
status of neuroblastomas, as evidenced by the observations620 Cell Reports 17, 609–623, October 4, 2016that high-risk neuroblastomas are histologically undifferentiated
or poorly differentiated and that expression of these metabolic
genes are downregulated during differentiation. In further sup-
port of the clinical significance of the metabolic program, we
found that pharmacological inhibition or genetic silencing of
either metabolic pathway is sufficient to inhibit the growth
and tumorigenicity of human neuroblastoma cell lines. These
findings suggest that transcriptional activation of the choles-
terol and serine-glycine synthesis pathways is crucial for the
pathogenesis and progression of high-risk neuroblastoma.
Our findings have implications for the development of new
therapeutic strategies that target this metabolic program in
high-risk neuroblastoma. The cholesterol/mevalonate pathway
has been implicated in cancer development (Freed-Pastor
et al., 2012; Gruenbacher and Thurnher, 2015; Silvente-Poirot
and Poirot, 2012), and statins have been shown to exhibit anti-tu-
mor effects (Clendening and Penn, 2012; Thurnher et al., 2012).
Our findings present a compelling case for statins as potential
therapeutics for high-risk neuroblastoma. Similarly, blocking
the serine-glycine pathway, either alone or in combination with
other therapies, may represent a promising therapeutic strategy
for high-risk neuroblastoma.
EXPERIMENTAL PROCEDURES
Neuroblastoma Sphere Culture
Neuroblastoma tumors were removed from TH-MYCN mice, minced, and
mechanically dissociated into single cells using a cell strainer (70 mm,
22363548, Thermo Fisher Scientific). Red blood cells were lysed in ACK
buffer (150 mM NH4Cl, 10 mM KHCO3, and 0.1 mM EDTA [pH 7.3]), and
dead cells were removed by passing through Ficoll-Paque Plus (17-1440-
02, GE Healthcare). Viable tumor cells were cultured in complete neural crest
cell culture medium (Etchevers, 2011). The medium was replaced every
3 days. After 3 weeks of culture, primary spheres were mechanically disso-
ciated into single cells by pipetting and were then expanded through weekly
dissociation of spheres.
To assess sphere-forming cell frequency in primary tumors (n = 5), 50,000
cells from each primary tumor were plated at clonal density of one cell per
microliter (Coles-Takabe et al., 2008; Pastrana et al., 2011) (2,000 cells/well,
six-well plates). Primary spheres were counted after 15–21 days in culture.
For serial sphere-forming assays, primary spheres were mechanically dissoci-
ated into single cells by pipetting, and500 cells were plated at 1 cell/well into
96-well plates. Secondary spheres were counted after 8 days in culture. 100
cells from each secondary sphere (n = 3 for each primary tumor) were plated at
one cell per well into 96-well plates for assessing their capacity to generate
tertiary spheres.
Tumor Transplantation
Freshly isolated primary tumor cells, sphere cells, or human neuroblastoma
cell lines in 200 mL serum-free DMEMwere injected subcutaneously into flanks
of recipient 129X1/SvJ and NOD.SCID/NCr mice. For serial tumor transplanta-
tion assays, single primary spheres from the clonal culture described above
were individually expanded for the generation of secondary tumors, which
were then dissociated into single cells and plated at clonal density. Single sec-
ondary spheres were again individually expanded for the generation of tertiary
tumors. The experiment was terminated when the first tumor(s) reached
0.5 cm in diameter or 4 months post-injection.
Patient Data
Patient data used in this study were described previously (Kocak et al., 2013;
Zhang et al., 2015). All analyses were conducted online using R2: Genomics
Analysis and Visualization Platform (http://r2.amc.nl), and the resulting figures
and p values were downloaded.
Statistics
Quantitative data are presented asmean ±SD andwere analyzed for statistical
significance by an unpaired, two-tailed Student’s t test or two-way ANOVA
using GraphPad Prism 6.0h for Mac.
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